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Abstract
Objective: Carbapenems are effective agents to treat multidrug‑resistant (MDR) strains 
of bacteria, including Pseudomonas aeruginosa. However, there is a potential threat of 
emergence of carbapenem‑resistant P. aeruginosa (CRPA). The aim of this study was to 
determine antibiotic susceptibility patterns and metallo‑beta‑lactamase (MBL)‑mediated 
resistance in clinical P. aeruginosa isolates. Materials and Methods: Different clinical 
specimens were subjected to conventional culture‑based identification of P. aeruginosa. 
Antimicrobial susceptibility patterns and MBL production were evaluated using the 
Kirby‑Bauer and combined double‑disk synergy test methods, respectively. Multiplex 
polymerase chain reaction was performed to investigate the presence of the blaIMP, blaVIM, 
blaNDM, blaSPM, and blaSIM genes. Results: A total of 71 clinical P. aeruginosa isolates 
were recovered, of which 28.17% were identified as CRPA. The most active antibiotics 
were colistin and polymyxin B (92.96% susceptibility to each). A total of 35% and 50% 
of CRPA isolates were MDR and extensively drug‑resistant (XDR), respectively. MBL 
activity was shown in 20% of CRPA. A total of 90%, 40%, and 5% of CRPA isolates 
harbored the blaIMP, blaVIM, and blaNDM genes, respectively. No correlation was found 
between the MBL‑encoding genes of P. aeruginosa and patient characteristics. Conclusion: 
Although the prevalence of CRPA in our therapeutic centers was relatively low, this rate 
of carbapenem resistance reflects a threat limiting treatment choices. A high prevalence of 
MDR/XDR phenotypes among the MBL‑producer isolates suggests the need for continuous 
assessment of antimicrobial susceptibility and surveillance of antibiotic prescription. In 
addition, infection control measures are needed to prevent further dissemination of these 
organisms.
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to the carbapenems in P. aeruginosa is often caused by imper‑
meability through alteration or loss of the porin OprD [6], 
increased expression of an efflux pump [7], or the production 
of class B metallo‑β‑lactamases (MBLs) [4].
MBLs that have been detected primarily in P. aeruginosa [8] 
are categorized in class B in the structural classification scheme 
and group 3 in the functional classification system [9]. Various 
types of MBLs, such as the IMP, VIM, SIM, SPM, GIM, and 
NDM families have been described in P. aeruginosa world‑
wide [4]. Class B carbapenemases can hydrolyze most β‑lactam 
Introduction
Pseudomonas aeruginosa, a member of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, P. aeruginosa, and 
Enterobacter species) group of pathogens, is responsible for 
life‑threatening nosocomial infections, especially in critically 
ill and immunocompromised patients and is known by poten‑
tial drug resistance mechanisms [1,2]. Multidrug‑resistant P. 
aeruginosa (MDR‑PA) is a matter of great concern as it not 
only causes severe and fatal infections but also increases 
the length of hospital stay, resulting in increased treat‑
ment costs [3]. Carbapenems are effective antibiotics against 
MDR‑PA infections [4]. However, their use in the management 
of infections is threatened by the development of carbape‑
nem‑resistant P. aeruginosa (CRPA) strains [4,5]. Resistance 
aLaboratory Sciences Research 
Center, Golestan University of 
Medical Sciences, Gorgan, Iran, 
bDepartment of Microbiology, 
Faculty of Medicine, Golestan 
University of Medical Sciences, 
Gorgan, Iran, cDepartment 
of Microbiology, School of 
Medicine, Iran University of 
Medical Sciences, Tehran, Iran
*Address for correspondence: 
Dr. Abdollah Ardebili, 
Department of Microbiology, Faculty of Medicine, Golestan University of 
Medical Sciences, Gorgan, Iran. 
E‑mail: ardebili_abdollah57@yahoo.com
Metallo‑β‑lactamase‑mediated resistance among clinical carbapenem‑resistant 
Pseudomonas aeruginosa isolates in northern Iran: A potential threat to 
clinical therapeutics
Abdol Ahad Dogonchia,b, Ezzat Allah Ghaemia,b, Abdollah Ardebilia,b*, Sajjad Yazdansetada,b, Abazar Pournajaf c
Original Article
Tzu Chi Medical Journal 2018; 30(2): 90‑96
Received : 06‑Aug‑2017
Revised : 01‑Sep‑2017
Accepted : 14‑Nov‑2017
Access this article online
Quick Response Code:
Website: www.tcmjmed.com
DOI: 10.4103/tcmj.tcmj_101_17
How to cite this article: Dogonchi AA, Ghaemi EA, Ardebili A, Yazdansetad S, 
Pournajaf A. Metallo‑β‑lactamase‑mediated resistance among clinical carbapenem‑resistant 
Pseudomonas aeruginosa isolates in northern Iran: A potential threat to clinical 
therapeutics. Tzu Chi Med J 2018;30(2):90‑6.
This is an open access journal, and articles are distributed under the terms of the 
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows 
others to remix, tweak, and build upon the work non-commercially, as long as 
appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Dogonchi, et al. / Tzu Chi Medical Journal 2018; 30(2): 90‑96
 91
group antibiotics except for monobactams (aztreonam). They 
are inhibited in vitro by metal chelators, such as ethylenedi‑
aminetetetraacetic acid (EDTA), while clavulanic acid has no 
activity against these enzymes [9].
MBL‑encoding genes are frequently located in mobile 
or transferable genetic structures, such as plasmids, trans‑
posons and integrons, which can contribute to their spread 
in different bacteria, including Acinetobacter species and 
Enterobacteriaceae [4]. We are several years away from imple‑
mentation of a therapeutic inhibitor of MBLs, and hence, their 
continuous spread is becoming an important challenge for anti‑
biotic therapy [10].
The present study was performed to characterize the preva‑
lence of carbapenem resistance, and MBL production among 
P. aeruginosa isolates from hospitalized patients in Gorgan, in 
northern Iran. Herein, we describe the susceptibility profiles 
and class B carbapenemase genes carried by the isolates, as it 
might help in the worldwide comparison of resistance mecha‑
nisms of MDR Gram‑negative bacilli.
Materials and Methods
Study population and species identification
This project was approved by the Ethics Committee of 
Golestan University of Medical Sciences with the ethical code 
number IR. GUMS. REC.1395.87. Informed consent was 
signed by all patients who were hospitalized at four thera‑
peutic centers, including 5th Azar, Sayyad Shirazi, Ayatollah 
Taleghani, and Hakim Jurjani hospitals. From February 2016 
to July 2017, different biological materials, including urine, 
respiratory tract samples, blood, eye swabs, wound swabs, ear 
swabs, and a heart biopsy were obtained. All specimens were 
cultured on MacConkey agar and nonselective blood agar 
media (Merck, Darmstadt, Germany). P. aeruginosa isolates 
were identified by standard microbiological and biochemi‑
cal methods, such as colony morphology and pigmentation, 
Gram staining, oxidase, catalase, motility, indole, citrate, and 
oxidative‑fermentative tests, and growth at 42°C. All isolates 
were then stored in tryptic soy broth stock (Merck, Darmstadt, 
Germany) with 15% glycerol at −80°C until used.
Antimicrobial susceptibility profiling
Antibiotic susceptibility profiles of all isolates were deter‑
mined using the Kirby‑Bauer diffusion testing method on 
Mueller–Hinton agar plates (Merck, Darmstadt, Germany), 
according to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI) [11]. The antibiotic disks (MAST, 
Merseyside, UK) used were as follows: imipenem (10 μg), 
meropenem (10 μg), ceftazidime (30 μg), piperacillin‑tazobac‑
tam (100 μg/10 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), 
gentamicin (10 μg), amikacin (30 μg), tobramycin (10 μg), 
polymyxin B (300 U), and colistin (10 μg). Quality control 
testing was performed using the recommended organisms, P. 
aeruginosa ATCC 27853 and E. coli ATCC 35218. To char‑
acterize patterns of multiple drug resistance, isolates were 
defined as MDR‑PA, extensively drug‑resistant‑PA (XDR‑PA), 
and pandrug‑resistant‑PA (PDR‑PA) according to Magiorakos 
et al. [12] as follows: MDR‑PA, if isolates were resistant to ≥1 
agent in ≥3 antimicrobial groups; XDR‑PA, if isolates were 
resistant to ≥1 agent in all but ≤2 groups; PDR‑PA, if iso‑
lates were resistant to all antimicrobials studied. Furthermore, 
all isolates that met criteria of resistance to any carbape‑
nem (imipenem or meropenem) tested, as characterized by the 
CLSI [11], were considered CRPA.
Phenotypic detection of metallo‑beta‑lactamase
CRPA cultures were evaluated for MBL production using 
the combined double‑disk synergy test (CDDST) [13]. In brief, 
100 mM EDTA solution (Merck, Darmstadt, Germany) as an 
MBL inhibitor (iMBL) was made by dissolving 3.72 g of diso‑
dium EDTA.2H2O in 100 mL of distilled water. The pH was 
adjusted to 8.0 by NaOH and sterilized by autoclaving. A 0.5 
McFarland suspension of the organism was inoculated onto 
Mueller–Hinton agar plates. Two disks each of imipenem (10 
μg) and ceftazidime (30 μg) antimicrobials were placed on 
the inoculated Mueller–Hinton plates at a distance of 2 cm. 
For both β‑lactam agents, 8 μL of iMBL solution was directly 
added to one of the disks. After an overnight incubation period 
at 37°C, an increase in the inhibition zone ≥8 mm around the 
combined disk compared to that the corresponding antimicro‑
bial disk alone was considered positive for an MBL [13]. An 
MBL‑producing strain of P. aeruginosa was used as the posi‑
tive control.
Detection of metallo‑beta‑lactamase determinants
All CRPA isolates were examined for MBL‑encoding genes, 
including blaIMP, blaVIM, blaNDM, blaSPM, and blaSIM, by a mul‑
tiplex polymerase chain reaction (PCR) assay using specific 
primers [Table 1] [14]. A DNA template was prepared using 
the boiling method. In brief, a few colonies of an overnight 
culture were suspended in 200 μL of sterile distilled water. 
The bacterial suspension was boiled for 15 min and cen‑
trifuged at 12000 rmp for 10 min, and the supernatant was 
transferred to a fresh Eppendorf tube as a template. PCR 
amplification was performed in 25 μL reaction mixture with 
2x Master Mix Red (Ampliqon, Herlev, Denmark) contain‑
ing 1 × PCR buffer ([Tris‑HCl, pH 8.5], [NH4]2S04, 4 mM 
MgCl2, 0.2% Tween20), 0.2 U/μL Taq DNA polymerase, 2 
mM MgCl2, and 0.4 mM of each deoxynucleotide, 0.2 μM of 
each primer (Macrogen, Seoul, Korea), 10 ng template DNA, 
and sterile distilled water. PCR was performed using the fol‑
lowing thermal cycling protocol: initial denaturation at 94°C 
for 10 min, followed by 36 cycles of denaturation at 94°C 
Table 1: Oligonucleotide primers used to amplify 
metallo‑β‑lactamase genes
Gene Primer (5’→3’) Amplicon size (bp)
blaIMP F: GGAATAGAGTGGCTTAAYTCTC
R: GGTTTAAYAAAACAACCACC
232
blaVIM F: GATGGTGTTTGGTCGCATA
R: CGAATGCGCAGCACCAG
390
blaSPM F: AAAATCTGGGTACGCAAACG
R: ACATTATCCGCTGGAACAGG
271
blaSIM F: TACAAGGGATTCGGCATCG
R: TAATGGCCTGTTCCCATGTG
570
blaNDM F: GGTTTGGCGATCTGGTTTTC
R: CGGAATGGCTCATCACGATC
621
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for 30 s, annealing at 52°C for 40 s, extension at 72°C for 
50 s and a final extension at 72°C for 5 min. PCR products 
were electrophoresed on 1.5% agarose gel stained with DNA 
safe stain (SinaClon, Tehran, Iran), then photographed under 
an ultraviolet transilluminator. Sequencing of the PCR ampli‑
cons was performed with anABI 3730 DNA analyzer (Applied 
Biosystems, Foster City, CA, USA), and then, the nucleo‑
tide sequences were compared with known sequences at 
the National Center for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/BLAST/).
Data analysis
SPSS software version 18.0 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis. Categorical 
and continuous quantitative variables were analyzed using 
Pearson’s Chi‑squared and independent samples t‑tests, respec‑
tively. Statistical significance in this study was a P < 0.05.
Results
Bacterial isolates
A total of 71 nonrepetitive P. aeruginosa isolates were recov‑
ered, of which 37 (52.12%) were from males and 34 (47.88%) 
were from females. The age distribution of patients was as 
follows: <1 year old (n = 13, 18.31%), 1–15 years old (n = 15, 
21.12%), 16–35 years old (n = 7, 9.86%), 36–55 years 
old (n = 9, 12.67%), and > 55 years old (n = 27, 38.03%). The 
origins of isolates were urine (n = 31, 43.66%), the respiratory 
tract (n = 28, 39.43%), blood (n = 5, 7.04%), eye swabs (n = 3, 
4.22%), wound wabs (n = 2, 2.81%), ear swab (n = 1, 1.41%), 
and heart biopsy (n = 1, 1.41%).
Antimicrobial susceptibility profile
According to results from the antibiotic susceptibility test, 
20 (28.17%) and 51 (71.83%) isolates were identified as CRPA 
and carbapenem‑susceptible (CSPA), respectively. CRPA 
isolates were recovered from the respiratory tract (n = 10, 
50%), urine (n = 5, 25%), blood (n = 3, 15%), and one 
wound and one ear swab (n = 1, 5% each). The resistance 
rates for β‑lactams, including imipenem, meropenem, ceftazi‑
dime, and piperacillin/tazobactam were 26.76% (n = 19), 
18.31% (n = 13), 22.53% (n = 16), and 18.31% (n = 13), 
respectively. The resistance rates for non‑β‑lactam antimicrobi‑
als, including ciprofloxacin, levofloxacin, gentamicin, amikacin, 
tobramycin, polymyxin B, and colistin were 25.35% (n = 18), 
29.57% (n = 21), 21.12% (n = 15), 15.49% (n = 11), 
19.72% (n = 14), 7.04% (n = 5), and 7.04% (n = 5), respec‑
tively. Polymyxin B and colistin showed the highest in vitro 
activity against the isolates, with a susceptibility rate 
92.96% (n = 66) for each; while the highest resistance rate was 
seen against levofloxacin (29.57%, n = 21).
Except for polymyxin B and colistin, the degrees of resis‑
tance for all antibiotics tested were significantly higher in the 
CRPA group than the CSPA group [Table 2]. Although a sig‑
nificant percentage of both CSPA and CRPA isolates showed 
susceptibility to polymyxin B (90.2% vs. 100%) and colis‑
tin (92.15% vs. 95%), CSPA isolates were significantly more 
susceptible to the remaining antibiotics tested. Based on the 
criteria mentioned earlier, 11.26% (n = 8) and 15.49% (n = 11) 
were identified as the MDR‑PA and XDR‑PA phenotype, 
respectively. The percentages of MDR‑PA and XDR‑PA 
among the CRPA were 35% and 50%, respectively; while the 
prevalence of MDR‑PA and XDR‑PA was low in the CSPA 
group (1.96% each).
Metallo‑beta‑lactamase activity and related genes
Of the 20 CRPA isolates, 4 (20%) were MBL‑positive 
with the CDDST [Figure 1], and all showed multi‑resistance 
patterns. Overall, 19 (95%) of CRPA isolates were found to 
carry MBL‑encoding determinants [Figure 2]. The presence of 
MBL‑encoding genes in CRPA isolates was not correlated with 
patient characteristics, including clinical specimen type, hos‑
pital ward, age, or gender (P > 0.06) [Table 3]. MBL genes 
detected were blaIMP (n = 18, 90%), blaVIM (n = 8, 40%), and 
blaNDM (n = 1, 5%). The blaIMP gene co‑existed with blaVIM in 
eight (40%) isolates. In addition, blaIMP co‑existed with the 
blaNDM gene in only one (5%) CRPA isolate. Sequencing data 
Table 2: Comparison of susceptibility of carbapenem‑resistant 
Pseudomonas aeruginosa and carbapenem‑susceptible 
Pseudomonas aeruginosa isolates to antibiotics tested
Antimicrobial 
agent
Number (%) of 
resistant isolates
P Number (%) of 
susceptible isolates
P
CRPA 
(n=20)
CSPA 
(n=51)
CRPA 
(n=20)
CSPA 
(n=51)
CAZ 12 (60) 4 (7.84) 0.0001 8 (40) 46 (90.2) 0.0001
PTZ 10 (50) 3 (5.88) 0.001 8 (40) 46 (90.2) 0.0001
CIP 12 (60) 6 (11.76) 0.0001 7 (35) 44 (86.27) 0.0001
LEV 13 (65) 8 (15.68) 0.0001 5 (25) 43 (84.31) <0.0001
GM 12 (60) 3 (5.88) 0.0001 8 (40) 47 (92.15) 0.0001
AK 8 (40) 3 (5.88) 0.007 12 (60) 48 (94.11) 0.007
TN 11 (55) 3 (5.88) 0.0001 9 (45) 48 (94.11) 0.0001
PB 0 5 (9.8) 0.9 20 (100) 46 (90.2) 0.9
CO 1 (5) 4 (7.84) 1 19 (95) 47 (92.15) 1
CAZ: Ceftazidime, PTZ: Piperacillin/tazobactam, CIP: Ciprofloxacin, 
LEV: Levofloxacin, GM: Gentamicin, AK: Amikacin, TN: Tobramicin, 
PB: Polymyxin B, CO: Colistin, CRPA: Carbapenem‑resistant PA, CSPA: 
Carbapenem‑susceptible PA, PA: Pseudomonas aeruginosa
Figure 1: Phenotypic combined double‑disk synergy test to detect 
metallo‑beta‑lactamase production in carbapenem‑resistant P. aeruginosa isolates. 
Imipenem and imipenem + EDTA disks and ceftazidime and ceftazidime + EDTA 
disks were used to detect metallo‑beta‑lactamase ‑producers. A zone diameter 
difference between the disks alone and the disks plus EDTA of ≥8 mm was 
interpreted as metallo‑beta‑lactamase production
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confirmed the presence of the blaIMP‑1, blaVIM‑2, and blaNDM‑1 
variants in isolates. No amplicon was obtained with primers tar‑
geting blaSPM, and blaSIM. All 4 isolates with MBL activity in 
the CDDST were positive for MBL genes, of which 1 (25%), 
1 (25%), and 2 (50%) isolates carried the blaIMP, blaVIM, and 
both genes, respectively. Furthermore, 15 (75%) of the CRPA 
which lacked MBL activity were positive for particular genes. 
Only one CRPA isolate was negative for MBL activity and any 
of the genes tested.
Discussion
Antimicrobial resistance is an unpleasant event with a 
rising impact on patient safety, especially in Intensive Care 
Units (ICUs). Acutely, ill patients are prone to colonization 
and infection by antibiotic‑resistant bacteria due to long‑term 
hospitalization repeated exposure to antimicrobial agents and 
implementation of invasive therapeutic procedures. This serious 
array of risk factors leads to a vicious cycle of increased 
infection rates, the increased necessity for broad‑spectrum anti‑
biotics, reduced antimicrobial efficacy, and increased selection 
of drug resistance [15].
Carrying acquired MBL determinants enables bacteria 
to become resistant to broad‑spectrum β‑lactam antibiotics, 
including carbapenems, which are often the “last resort” agents 
for Gram‑negative pathogens causing hospital‑associated 
infections. Furthermore, MBL‑producing pathogens usually 
develop to the multi‑resistant phenotype, because they originate 
Table 3: Characteristics of carbapenem‑resistant Pseudomonas aeruginosa isolated from hospitalized patients
Isolate Patient characteristics Resistance pattern MDR XDR CDDST MBL genes
Age (year) Gender Hospital ward Isolation material IMP VIM NDM SIM SPM
PA2 26 Female Emergency room Blood IMI, MEM, CAZ, PTZ + ‑ ‑ + + ‑ ‑ ‑
PA3 78 Female Internal medicine Respiratory tract IMI, CAZ, PTZ, LEV ‑ + + ‑ + ‑ ‑ ‑
PA6 83 Female ICU Respiratory tract IMI, GM, CAZ, PTZ, CIP, 
LEV
‑ + ‑ + + ‑ ‑ ‑
PA7 71 Female ICU Respiratory tract IMI, MEM, GM, AK, TN, 
PTZ, CIP, LEV
‑ + ‑ + + ‑ ‑ ‑
PA9 63 Male Internal medicine Respiratory tract IMI, MEM, GM, TN, CAZ, 
CIP, LEV
‑ + ‑ + ‑ + ‑ ‑
PA11 79 Male Outpataint Urine IMI, MEM, GM, TN, CIP, 
LEV
+ ‑ ‑ + ‑ ‑ ‑ ‑
PA13 79 Male Emergency room Respiratory tract IMI, MEM, GM, AK, TN, 
CIP
+ ‑ ‑ + ‑ ‑ ‑ ‑
PA15 20 Female Internal medicine Respiratory tract IMI, MEM, GM, AK, TN, 
CAZ, CIP, LEV
‑ + + + ‑ ‑ ‑ ‑
PA20 9 Male Infectious diseases Ear swab IMI ‑ ‑ ‑ + ‑ ‑ ‑ ‑
PA21 52 Female Outpataint Urine IMI ‑ ‑ ‑ + + ‑ ‑ ‑
PA22 25 Male Outpataint Urine IMI, GM, AK, CIP, LEV + ‑ ‑ + ‑ ‑ ‑ ‑
PA25 68 Male ICU Respiratory tract IMI, MEM, GM, CIP, LEV + ‑ + + + ‑ ‑ ‑
PA31 1 Female Outpataint Urine MEM ‑ ‑ ‑ + ‑ ‑ ‑ ‑
PA33 68 Male Infectious diseases Respiratory tract IMI, MEM, GM, AK, TN, 
CAZ, PTZ, CIP, LEV
‑ + ‑ + ‑ ‑ ‑ ‑
PA44 7 Female Emergency room Wound swab IMI, MEM, GM, AK, TN, 
CAZ, PTZ, CIP
‑ + + + + ‑ ‑ ‑
PA45 81 Female Outpataint Urine IMI, CIP, LEV, CO + ‑ ‑ + ‑ ‑ ‑ ‑
PA48 1 Female PICU Blood IMI, MEM, CAZ, PTZ + ‑ ‑ + + ‑ ‑ ‑
PA52 46 Male Nephrology Blood IMI, MEM, GM, AK, TN, 
CAZ, PTZ, CIP, LEV
‑ + ‑ ‑ ‑ ‑ ‑ ‑
PA55 1 Female ICU Respiratory tract IMI, MEM, CAZ, PTZ, LEV ‑ + ‑ + ‑ ‑ ‑ ‑
PA71 72 Female Emergency room Respiratory tract IMI, GM, AK, TN, CAZ, 
PTZ, CIP, LEV
‑ + ‑ + ‑ ‑ ‑ ‑
IMI: Imipenem, MEM: Meropenem, CAZ: Ceftazidime, PTZ: Piperacillin/tazobactam, CIP: Ciprofloxacin, LEV: Levofloxacin, GM: Gentamicin, 
AK: Amikacin, TN: Tobramicin, CO: Colistin, PA: Pseudomonas aeruginosa, MDR: Multidrug‑resistant, XDR: Extensively drug‑resistant, 
CDDST: Combined double‑disk synergy test, MBL: Metallo‑β‑lactamase, ICU: Intensive Care Unit, PICU: Pediatric ICU, +: Yes, ‑: No
Figure 2: Agarose gel electrophoresis of multiplex PCR products. Lanes 1 and 4, 
isolates with blaIMP (232 bp) and blaVIM (390 bp) genes; Lane 2, isolate with the 
blaIMP (232 bp) gene; Lane 6, isolates with blaIMP (232 bp) and blaNDM (621 bp) genes; 
Lanes 3 and 5, isolates without any genes studied; Lane 7, negative control (distilled 
water); M, 100 bp DNA ladder
Dogonchi, et al. / Tzu Chi Medical Journal 2018; 30(2): 90‑96
94 
nosocomially and acquired MBL‑related genes typically cluster 
with other drug resistance determinants in the variable region 
of multi‑resistance integrons [16]. These reasons explain why 
infections caused by MBL producers can pose a great chal‑
lenge for antibiotic chemotherapy.
In this study, we described clinical carbapenem‑resistant 
MDR/XDR P. aeruginosa isolates, which are capable of pro‑
ducing MBL type carbapenemase. Although the prevalence of 
CRPA in the present study was relatively low (28.17%), this 
rate of carbapenem resistance reflects a threat limiting treat‑
ment choices in our therapeutic centers. The ratio of CRPA 
differs by geographic region, kind of infection and specimen 
source, and selective pressure due to antibiotics [17]. In a 
recent study in Algeria, Meradji et al. [18] found that 18.75% 
of clinical P. aeruginosa isolates were resistant to carbapen‑
ems. In our country, there are different rates of resistance to 
carbapenems in P. aeruginosa. Mirsalehian et al. [19] reported 
a 100% rate of carbapenem‑resistant and MDR‑PA isolates 
from burn patients in Tehran, the capital of Iran. Furthermore, 
Farajzadeh Sheikh et al. [20] showed that among P. aerugi-
nosa isolates from Ahvaz in Southwest Iran, 58.7% and 31.8% 
were resistant to imipenem and meropenem, respectively, and 
44.4% showed multiple‑drug resistance. However, lower preva‑
lences of CRPA isolates were reported previously by Tarhani 
et al. [21], and Forozsh et al. [22]. In addition, we found a 
significantly higher multi‑resistance rate in the CRPA group 
compared with the CSPA group, and the most effective antibi‑
otics against both groups were polymyxin B and colistin. These 
findings indicate that polymyxins have increasingly become the 
last resort treatment for multi‑resistant P. aeruginosa infections.
Various phenotypic methods, such as the MBL Etest, dou‑
ble‑disk synergy test (DDST), and CDSST have been suggested 
for screening for MBL producing P. aeruginosa. Although both 
the DDST and CDDST are simple to perform and cheaper than 
the MBL Etest, they have shown incompatible results depend‑
ing on the methodology used, β‑lactam substrates, iMBLs, and 
the bacterial genus tested [13,20,23,24]. In the present study, 
20% of all CRPA isolates were positive for MBL production on 
the phenotypic screening test, whereas 95% were positive for 
MBL‑encoding genes. The reported low rates of MBL activity 
among the CRPA could be because detection of carbapenemase 
activity in clinical isolates is challenging work. In addition, 
discordant results for MBL detection between the pheno‑
typic and genotypic methods were reported in Inacio et al.’s 
study [25], where 30% of P. aeruginosa were MBL producers 
with the Etest and DD methods using several iMBLs, whereas 
87.5% were positive for the blaSPM‑1, and blaVIM‑1 genes. In this 
manner, these MBL producers might act as silent reservoirs of 
such resistance determinants, with the ability to spread [26].
Overall, blaIMP and blaVIM are the most prevalent genes 
encoding MBLs detected in many regions, including 
Iran [27,28]. However, our study is in contrast to the findings 
obtained by Hakemi Vala et al. [29] and Bejestani et al. [30] 
in Tehran, Iran, who reported no blaVIM producing‑P. aerugi-
nosa from clinical materials. There are few studies reporting 
the incidence of blaNDM positive P. aeruginosa in our country. 
Most recently, Haghi et al. [31] found two clinical MDR‑PA 
harboring the blaNDM‑1 in Zanjan, Iran. Although only one CRPA 
isolate was identified to carry this gene in the present study, it 
is of concern as blaNDM producers can spread rapidly and this 
finding implies that numerous new blaNDM cases will be found 
in the near future [32]. In addition, we found one non‑MBL 
isolate negative for all genes tested. Therefore, the carbapenem 
resistance ability of the latter isolate may be mediated by other 
resistance mechanisms, such as loss of the oprD outer mem‑
brane protein‑encoding gene, up‑regulated efflux pumps, and 
production of other carbapenemases [33]. Further investigation 
is needed by our research group to address as many of these 
resistance mechanisms as possible.
Some correlation between the MBL‑encoding genes of 
P. aeruginosa and patient characteristics has been demon‑
strated [34‑36]. In a study in Brazil, Lucena et al. [34] found 
that ICU stay and urinary tract infections serve as signifi‑
cant risk factors for MBL‑positive P. aeruginosa infections. 
Conversely, in two individual studies, Shirani et al. [37] and 
Zavascki et al. [38] found no significant correlations between 
MBL‑positive P. aeruginosa and clinical characteristics of 
patients. Similarly, no specific characteristics of patients, includ‑
ing age, gender, hospitalization ward, and source of the isolate 
were associated with a higher frequency of MBL‑positive P. 
aeruginosa infections in our study.
Herein, we demonstrated carbapenem‑resistant MDR/XDR 
P. aeruginosa isolates with carbapenemase activity. IMP‑ and 
VIM‑producing P. aeruginosa were the MBL‑producing strains 
present at our therapeutic centers. The emergence of carbape‑
nem resistance reflects a threat limiting treatment choices and 
suggests the need for ongoing epidemiological and antimi‑
crobial susceptibility studies and longitudinal surveillance of 
antibiotic prescription. The continuous presence of such prob‑
lematic organisms and their intra‑hospital and inter‑hospital 
spread is a matter of concern and should be taken into consid‑
eration by hospital infection control teams.
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